The international forum, organized by EUROoCS and the International MPS Society, brought together leading scientists, industry representatives, and patient groups to discuss the latest developments in mucopolysaccharidosis (MPS) and related diseases.
A particular highlight was myotwin’s poster presentation “Heart Attack in a Dish.” The model, which replicates cardiovascular disease mechanisms at the cellular level, attracted strong interest from the international MPS community.
In addition, Dr.-Ing. Jan Pietras, co-founder of myotwin, contributed to the “Beat and Breath” session. He presented the company’s High-Content Screening Platform and joined discussions on the future of innovative disease models.
The conference was marked by lively discussions, inspiring presentations, and valuable exchange with the scientific community. myotwin extends its gratitude to EUROoCS and the International MPS Society for organizing such an outstanding event and looks forward to presenting further progress at next year’s conference.
About myotwin
myotwin is a biotech company specializing in human–relevant, preclinical testing systems for the development of cardiovascular drugs. With its proprietary myoScreen platform, myotwin enables the simultaneous measurement of contraction force, tissue stiffness, calcium dynamics, and electrical activity—directly on human heart tissue.
As a next step, myotwin is developing myoAI, a digital twin of the heart muscle that uses artificial intelligence to predict the efficacy and toxicity of drugs. This is giving rise to a new generation of precise, data-driven drug development.
The Germany-based company works closely with research institutions, industry partners, and investors to advance innovative therapies for cardiovascular diseases more quickly and in a more targeted manner. For more information, visit www.myotwin.com.
Forward–looking statements
This communication may contain forward–looking statements based on current assumptions and forecasts made by myotwin’s management. Various known and unknown risks, uncertainties, and other factors could cause the actual results, financial position, development, or performance of the company to differ materially from the estimates given here. These factors include those described in myotwin’s public reports, which are available on the myotwin website at www.myotwin.com. The company assumes no obligation to update such forward-looking statements or to adapt them to future events or developments.
